Evidence map›Paper›PMID 18463168›Full record

ArticleJournal of the American Society of Nephrology : JASN2008

Association of oral calcitriol with improved survival in nondialyzed CKD.

Abigail B Shoben, Kyle D Rudser, Ian H de Boer, Bessie Young, Bryan Kestenbaum

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 255 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Evidence-based practice guideline for the treatment of CKD.Clinical and experimental nephrology · 2009
    Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013
    Trial
  10. Trial
  11. Trial
  12. Racial differences in markers of mineral metabolism in advanced chronic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2012
    Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Abigail B ShobenDepartment of Biostatistics, Puget Sound Veterans' Affairs Medical Center, Seattle, WA, USA.
Kyle D Rudser
Ian H de Boer
Bessie Young
Bryan Kestenbaum
VA Puget Sound Health Care System · US

Funding

Cardiac Outcomes Associated with Renal OsteodystrophyK23DK063274 · NIDDK · UNIVERSITY OF WASHINGTON · PI KESTENBAUM, BRYAN R · 2003 to 2007
$643k
NIDDK NIH HHS K23 DK063274NIDDK NIH HHS K23 DK63274-01
6 · The paper itself

Abstract

Parenteral vitamin D is associated with improved survival among long-term hemodialysis patients. Among nondialyzed patients with chronic kidney disease (CKD), oral activated vitamin D reduces parathyroid hormone levels, but the impact on clinical outcomes is unknown. We evaluated associations of oral calcitriol use with mortality and dialysis dependence in 1418 nondialysis patients with CKD and hyperparathyroidism in the Veterans' Affairs Consumer Health Information and Performance Sets database. Incident calcitriol users and nonusers were selected on the basis of stages 3 to 4 CKD, hyperparathyroidism, and the absence of hypercalcemia before calcitriol use and then were matched by age and estimated kidney function. During a median follow-up of 1.9 yr, 408 (29%) patients died and 217 (16%) initiated long-term dialysis. After adjustment for demographics; comorbidities; estimated kidney function; medications; and baseline levels of parathyroid hormone, calcium, and phosphorous, oral calcitriol use was associated with a 26% lower risk for death (95% confidence interval 5 to 42% lower; P = 0.016) and a 20% lower risk for death or dialysis (95% confidence interval 1 to 35% lower; P = 0.038). The association of calcitriol with improved survival was not statistically different across baseline parathyroid hormone levels. Calcitriol use was associated with a greater risk for hypercalcemia. In conclusion, oral calcitriol use is associated with lower mortality in nondialysis patients with CKD.

Indexed as

Administration, OralAgedAged, 80 and overCalcitriolCase-Control StudiesFemaleHumansHyperparathyroidism, SecondaryIdahoMaleMiddle AgedPacific StatesRenal DialysisRenal Insufficiency, ChronicVeteransVitaminsCalcitriolVitamins

Identifiers

PMID18463168
PMCPMC2488261
OpenAlexW2166775378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.